NCT04245215View on ClinicalTrials.gov

Loss of RESponse to Ustekinumab Treated by Dose Escalation

PHASE3CompletedINTERVENTIONAL
Enrollment

108

Participants

Timeline

Start Date

March 11, 2020

Primary Completion Date

September 25, 2024

Study Completion Date

September 25, 2024

Conditions
Crohn Disease
Interventions
DRUG

Ustekinumab

re-induction and dose escalation form every 8 weeks to every 4 weeks only in arm 2

Trial Locations (1)

1930

Ingrid Arijs, Zaventem

All Listed Sponsors
collaborator

Janssen Cilag N.V./S.A.

INDUSTRY

lead

Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW

OTHER

NCT04245215 - Loss of RESponse to Ustekinumab Treated by Dose Escalation | Biotech Hunter | Biotech Hunter